Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actelion’s Opsumit Ramps Up As Tracleer Patent Loss Gets Closer

This article was originally published in The Pink Sheet Daily

Executive Summary

The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.

You may also be interested in...

Actelion Grows Its PAH Franchise With Uptravi Approval

Broad label for oral product could help Actelion weather the loss of Tracleer to generic competition.

Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip

Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts